In the most notable company news over the past few months, December 2009 saw Latvian joint-stock pharmaceutical company Olainfarm entered into an agreement with international pharmaceutical company Arrow Group to start supplying active pharmaceutical ingredients (APIs) and tablets of memantine in Canadian and Australian markets. Around the same time, the TGA approved the registration of CSLs Panvax H1N1 Vaccine Junior, which will be used to vaccinate children aged 6 months to 9 years against the swine flu epidemic. Similarly, Aurobindo Pharma Australia, a whollyowned subsidiary of Indian drug manufacturer Aurobindo Pharma, obtained TGA approval for the registration of central nervous system (CNS) treatment citalopram hydrobramide tablets in 10mg, 20mg & 40mg strengths, illustrating the companys desire to take advantage of the rising demand for generics.
Key Topics Covered:
Executive Summary
SWOT Analysis
Pharmaceutical Business Environment Ratings
Australia - Market Summary
Regulatory Regime
Industry Trends and Developments
Industry Forecast Scenario
Competitive Landscape
Company Profiles
Sigma Pharmaceuticals Australian Pharmaceutical Industries Alphapharm (incorporated into Mylan) Herron Pharmaceuticals Mayne Pharma (Hospira) CSL Pfizer Sanofi-Aventis GlaxoSmithKline Merck Sharp & Dohme (Australia) Novartis AustraliaBMI Methodology
researchandmarkets/research/bbd2fd/australia_pharmace